DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

(±)-Mirtazapine (REMERON) 15–45 O 5-HT, NE 0 0 4+ 0/+ 0 0/+ 0/+ 0 0
Nefazodone (SERZONE) 200–400 O 5-HT 0 0 3+ 0 0 2+ 0/+ 0/+ 0/+
Trazodone (DESYREL) 150–200 O 5-HT 0 0 3+ 0 0 2+ + + 0/+
Monoamine Oxidase Inhibitors
Phenelzine (NARDIL) 30–60 O NE, 5-HT, 0/+ 0 + + 0 0/+ + 3+ 0
DA
Tranylcypromine (PARNATE) 20–30 O NE, 5-HT, 2+ 0 0 + 0 0/+ + 2+ 0
DA
(–)-Selegiline (ELDEPRYL) 10 O DA, ?NE, 0 0 0 0 0 0 0 + 0
?5-HT
Note: Most of the drugs are hydrochloride salts, but SURMONTIL and LUVOX are maleates; CELEXA is a hydrobromide, and REMERON is a free-base. Selegiline is approved for early Parkinson disease, but may
have antidepressant effects, especially at daily doses 20 mg, and is under investigation for administration by transdermal patch. a Both higher and lower doses are sometimes used, depending on an individual
patient’s needs and response to the drug; see the literature and FDA-approved dosage recommendations.
O, oral tablet or capsule; I, injectable; NE, norepinephrine; 5-HT, serotonin, DA, dopamine; 0, negligible; 0/+, minimal; +, mild; 2+, moderate; 3+, moderately severe; 4+, severe.
Other significant side effects for individual drugs are described in the text.
CHAPTER 15
DRUG THERAPY OF DEPRESSION AND ANXIETY DISORDERS
403